
Home » ACTELION SLUMPS ON CLAZOSENTAN STUDY OUTCOME
ACTELION SLUMPS ON CLAZOSENTAN STUDY OUTCOME
June 19, 2006
Swiss pharmaceutical company Actelion Ltd Monday said a study of its brain artery drug clazosentan showed that more time is needed to determine whether the product is effective, in a major setback that sent the shares sharply lower.
Therapeutics Daily
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Jan
-
26Jan
-
27Jan
-
27Jan
-
09Feb
-
10Feb